HC Wainwright set a $12.00 price objective on Eyenovia (NASDAQ:EYEN) in a research note published on Tuesday. The brokerage currently has a buy rating on the stock.

Several other research analysts also recently issued reports on EYEN. Zacks Investment Research upgraded shares of Eyenovia from a hold rating to a buy rating and set a $6.25 target price on the stock in a research note on Friday, August 17th. ValuEngine upgraded shares of Eyenovia from a hold rating to a buy rating in a research note on Thursday, November 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $17.63.

NASDAQ:EYEN opened at $3.95 on Tuesday. Eyenovia has a one year low of $2.60 and a one year high of $10.74.

Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, November 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). As a group, research analysts expect that Eyenovia will post -1.65 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. bought a new position in shares of Eyenovia in the third quarter worth approximately $157,000. Fairpointe Capital LLC bought a new position in shares of Eyenovia in the second quarter worth approximately $313,000. Finally, Uniplan Investment Counsel Inc. lifted its stake in shares of Eyenovia by 11.8% in the third quarter. Uniplan Investment Counsel Inc. now owns 385,624 shares of the company’s stock worth $1,550,000 after buying an additional 40,624 shares in the last quarter. Hedge funds and other institutional investors own 12.28% of the company’s stock.

About Eyenovia

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Further Reading: How much money do you need to begin day trading?

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.